We thank our past and present partners:
Graduated in 2000 from HEC, the leading French Business School, Wandrille started his career within M & A at JP Morgan, then became an entrepreneur. After 2 years at SG Capital Europe, a PE fund, he joined WCP, a mid-cap LBO fund upon its creation in 2005. In 2012, he joined POI, shareholder of Mutabilis, as CBO/CFO, and is today CEO of Mutabilis.
François
has 25 years of experience in drug discovery. After 6 years at Pfizer in
allergy and respiratory diseases, François joined Mutabilis in 2004 to explore
the possibilities of inhibiting bacterial pathogenicity. Before focusing on
discovery of Dabocins, he contributed to the development of a new class of
antibacterials, the FabI inhibitors and a new class of antiretrovirals, the
allosteric inhibitors of HIV integrase. François is co-author of 24
articles and co-inventor of 11 patents.
Sophie has more than 25 years of experience in medicinal chemistry. After 10 years at Cephalon, Sophie started to work on the promising diazabicyclooctane scaffold at Novexel in 2007, where she discovered improved Avibactam derivatives. Following the acquisition of Novexel by AstraZeneca in 2010, Sophie joined Mutabilis where she now heads Medicinal Chemistry, a team entirely dedicated to the discovery of Dabocins antibacterials. She co-authored 8 publications and 18 patents.